16.9 C
New York
Thursday, May 19, 2022

Crinetics Pharmaceuticals, Inc. (CRNX) stock surged in the Current Market; here is why?

Crinetics Pharmaceuticals Inc. (CRNX) stock gained in the current market after announcing underwritten public offering. CRNX stock values at $26.59, earning more than 19.6% from the previous close. CRNX stock closed at $22.22 at the end of the last trading session with a trading volume of 262.81K shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Global Pharmaceutical Industry Market Size and trends

Crinetics Pharmaceuticals, Inc. (CRNX) is a player in the pharmaceutical industry focused on treating rare endocrine diseases and related tumors.

This sector was worth roughly $100.9 billion in 2020. The global pharmaceutical business will rise 14.8% to $267.4 billion in FY27. During COVID19, the pharmaceutical industry focused on viral vectors in the virotherapy and vaccine industries to develop effective vaccines and pharmaceutical therapeutics. Lessons learned from the COVID19 pandemic will help these efforts.

North America had 46% of the global pharmaceutical market in FY20. The Asia-Pacific medications market accounted for 26% of the worldwide total. Africa has the world’s smallest pharmaceutical industry.

The pharmaceutical industry’s manufacturing sector is expected to grow even faster. Manufacturers of pharmaceuticals worldwide benefit from increased attention to elderly and pediatric patients, rising cardiovascular and diabetes rates, and an increase in persons seeking home healthcare. The global pharmaceutical manufacturing business is expected to grow at a CAGR of 12.8% from FY21 to FY30.

CRNX: Public Offering

Ann announced in the press release about the public offering. A total of 5.6 million shares have been offered at a price of $22.22 per share. In this offering, Crinetics will be selling all of its shares for sale. Crinetics expects to receive approximately $125.0 million in gross proceeds from the offering, excluding underwriting discounts and commissions, and other offering costs. If all criteria are met, the offering is projected to conclude on or around April 18, 2022.

In addition to funding paltusotine, CRN04777, CRN04894, and other R&D activities, Crinetics plans to utilize the net proceeds from the proposed offering to support working capital and other company purposes.


Being a player in treating rare tumors, the company has generated revenue of $1 million at the end of fiscal 2021. CRNX recorded this revenue in the fourth quarter. The company is expected to perform well in fiscal 2022.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles